�����ƽ��

In drug discovery, the gastrointestinal system is critical for evaluating absorption, metabolism, and safety. Human in vitro intestinal models enable you to assess permeability, transport, and first-pass metabolism, while hepatic systems support studies of metabolic function, cytochrome P450 (CYP)-mediated drug-drug interactions, and drug-induced liver injury (DILI). Pancreatic organoid and progenitor systems further enable modeling of metabolic dysfunction and therapeutic response. Together, these platforms support the development and implementation of new approach methodologies (NAMs) by helping you identify pharmacokinetic risks and safety liabilities in scalable, physiologically relevant human systems.

By incorporating gastrointestinal models into your workflow, you can generate mechanistic insight into compound behavior before clinical evaluation. Measure functional, metabolic, and molecular endpoints to identify predictive biomarkers, optimize compounds, and improve safety margins and therapeutic index. Integrating these systems earlier in development enables proactive de-risking and more confident decision-making.

Explore in vitro gastrointestinal tools for your NAM development.